| Literature DB >> 34566552 |
Boning Qiu1, Nils Bessler2, Kianti Figler1, Maj-Britt Buchholz2, Anne C Rios2, Jos Malda3,4, Riccardo Levato3,4, Massimiliano Caiazzo1,5.
Abstract
To date, pharmaceutical progresses in central nervous system (CNS) diseases are clearly hampered by the lack of suitable disease models. Indeed, animal models do not faithfully represent human neurodegenerative processes and human in vitro 2D cell culture systems cannot recapitulate the in vivo complexity of neural systems. The search for valuable models of neurodegenerative diseases has recently been revived by the addition of 3D culture that allows to re-create the in vivo microenvironment including the interactions among different neural cell types and the surrounding extracellular matrix (ECM) components. In this review, the new challenges in the field of CNS diseases in vitro 3D modeling are discussed, focusing on the implementation of bioprinting approaches enabling positional control on the generation of the 3D microenvironments. The focus is specifically on the choice of the optimal materials to simulate the ECM brain compartment and the biofabrication technologies needed to shape the cellular components within a microenvironment that significantly represents brain biochemical and biophysical parameters.Entities:
Keywords: 3D culture; Parkinson's disease; biofabrication; disease modeling; hydrogels
Year: 2020 PMID: 34566552 PMCID: PMC8444304 DOI: 10.1002/adfm.201910250
Source DB: PubMed Journal: Adv Funct Mater ISSN: 1616-301X Impact factor: 18.808
Figure 1Schematic representation of personalized in vitro bioprinted neural tissue models. A) Derivation of neural cells from somatic cells of an individual through direct cell reprogramming or induced pluripotent stem cell (iPSC) approach. B) Bioprinting with patient‐specific neural cells to generate neural tissue models conveying features of neuronal circuit and blood–brain barrier formation. C) Intended applications with bioprinted neural tissue models.
Comprehensive overview of common bioprinting techniques and its applicability for neural modeling from the last 5 years
| Printing modalities | Reported printed features width | Cell type | Viability readout | Advantages and salient achievements | Limitations and challenges | |
|---|---|---|---|---|---|---|
|
| ||||||
| Inkjet | 50–80 μm[
| Rat (adult) glial and retinal cells[
| Trypan blue: ≈69% (postprinting)[
|
Delivery rate: ≈7 mm3 min−1[
Fabrication rate: 1–10k droplets s−1[
Bioink viscosity range: 2–20 mPa s[
Compatible with other biofabrication strategies involvingextrusion of thermoplastics[
|
Limited structural integrity and shape fidelity[
Reported cell numbers varied per deposited drop[
Low cell densities (<1 × 106; 2100 cells mm−1 (physiological) vs 20 cells mm−1 (printed))[
| |
| ≈300 μm[
| P2–4 rat primary retinal ganglion cells (RGCs)[
| Calcein AM/SYTOX: 1.2‐fold increased survivability (printed vs nonprinted) if growth medium was added to the bioink formulation (postprinting)[
| ||||
| Extrusion‐based | 200 μm[
| hiPSC‐derived spinal progenitor cells (sNPCs) and oligodendrocyte progenitor cells (OPCs)[
| Calcein AM/EthD:5, 15, 30 min |
Wide range of viscosity (30 mPa s to 60 kPa s)[
Achieved in situ reprogramming and differentiation[
High cell densities (8 × 107 cells mL−1)[
Shown formation of intercellular connections in neuronal networks[
High density of cell aggregates are printable, microfluidic‐chip enabled complex prints[
Easy accessibility: RepRap hardware[
Embedding bioprinting strategies (e.g., FRESH)[
|
Poor structural integrity and shape fidelity in low‐viscosity inks, and potential cell damage from shear forces while extruding[
Slow printing speed may lead to gel dehydration thus requiring strategies to control the printing environment[
| |
| ≈410 μm (nozzle diameter)[
| Adult fibroblasts[
|
VB‐48/propidium Iodide (PI): ≈65% (24 h post printing) CCK‐8: ≈85% (recovery after day 7)[
| ||||
| ≈200 μm (nozzle diameter)[
| hiPSC[
| PrestoBlue: proliferation over 9 days of culture[
| ||||
| ≈100 μm (nozzle‐ϕ)[
| hiPSC‐derived neural precurs or cells (NPCs)[
| Calcein AM/EthD: ≈80% (postprinting)[
| ||||
| ≈400 μm (anticipated by aggregate size)[
| hiPSC‐derived neural aggregates[
|
Calcein AM/EthD: ≈95% (day10), ≈65% (day 15) Guava ViaCount (FACS): ≈90% (day 6)[
| ||||
| Optic‐based | ||||||
| Laser‐induced forward transfer (LIFT) | ≈200 μm[
| E15 rat primary dorsal root ganglia (DRG)[
|
Live‐Dye /PI: ≈85% (24 h post printing)[
|
Successful prints performed with hyaluronic acid and Matrigel[
Neurite growths reported[
Proven in situ differentiation of bioprinted cells[
|
Low cell density: ≈80 cells per drop[
Limited manufacturer diversity might affect device accessibility[
| |
| Not assessed[
| hiPSC[
|
Trypan Blue: ≈82% (2–3 h post printing)[
| ||||
| Stereolitho‐graphy (SLA) | ≈190 μm[
| Mouse NSCs (NE‐4C)[
|
Calcein AM/PI: ≈100–70%, 40–120 mW laser power)[
|
≈5 μm micrometer‐scale resolution a chievable[
Custom devices a vailable[
Combined with 3D printing using PCL fibers[
Used with conductive graphene‐loaded bioinks[
|
Potential cell damage due to UV light exposure Laser output affects cell survival[
Potential toxicity from photosensitive resins and initiators[
| |
| ≈1k μm[
| Mouse NSCs[
|
CCK‐8: Proliferation over 5 days of culture[
| ||||
|
Digital light processing (DLP) | 50–100 μm[
| No current report on the bioprinting of cells of neuronal lineage |
Delivery rate: ≈20 mm3 min−1[
High Resolutions <100 μm achievable[
Easily accessible: Commercial projectors[
Biocompatible polyethylene glycol diacrylate (PEGDA) and Gel‐MA resins already available[
|
Potential cell damage due to UV light exposure Potential toxicity from photosensitive resins and initiators[
| ||
| Two‐photon polymerization (2PP) | <1 μm[
|
Highest lateral resolution ≈100 nm[
Suitable for nano‐ and micropatterning potential |
Costly laser‐based equipment[
Potential toxicity from initiators[
| |||
Figure 2Common bioprinting techniques can be categorized into nozzle‐based or optical‐based printing methods. Nozzle‐driven printing can generate either filaments or droplets, based on the modality of dispensing of the material. Filament geometries are produced by mechanical forces (applied via piston, pneumatic devices, or screw‐driven extruders) while droplet geometries are obtained by localized heating or pressure increase within a nozzle. Another drop‐on‐demand technique (laser‐induced forward transfer, LIFT) relies on a pulsed laser transferring energy in the form of heat to a water‐based bioink, propelling it in the form of a droplet onto a moving collector plate. Additionally, optical bioprinting methods can be based on localized crosslinking of a photosensitive, cell‐laden resin, either by means of laser scanning (SLA) or digital light projection (DLP) driven by a micromirror array.
Materials used as bioink components for the biofabrication of functional constructs capturing CNS functions
| Main ink components | Printing method | Main findings and neuron functions observed | Ref. |
|---|---|---|---|
| Cell culture media | Inkjet | Preserved high viability postprinting and ability to form neurite outgrowth comparable to nonprinted cells |
[
|
| Dulbecco's phosphate‐buffered saline solution and fibrin | Inkjet | Preserved viability post‐printing. Healthy electrophysiological activity, as measured with patch‐clamp tests. |
[
|
| Polyethylene glycol diacrylate (PEGDA) and gelatin methacryloyl (GelMA) | Digital light projection | Cells were seeded onto printed scaffolds, fabricated to mimic the geometry of the rat and human spinal cord Cell‐laden scaffolds implanted in rodents showed axonal regeneration and partially restored impaired locomotor functions |
[
|
| Carboxymethyl‐chitosan and agarose blend | Extrusion | Printed cells were able to differentiate into both neurons and neuroglia. Formation of synaptic contacts in 3D |
[
|
| RGD‐modified gellan gum | Coaxial extrusion | Printing of a multilayered construct, with cells in the first and last layers. Neurons sprout processes through the middle layers, mimicking the brain cortex |
[
|
| GelMA | Extrusion | A compartment with glioblastoma multiforme (GBM) cells was encased in a printed macrophage‐laden gel. GBM cells recruit macrophages and trigger their differentiation to tumor‐associated macrophages. Co‐culture boosts the invasion of GMB in the surrounding gel |
[
|
| Dopamine‐functionalized GelMA | Extrusion | Dopamine functionalization did not boost proliferation. Enhanced differentiation of NSCs into maturing neurons |
[
|
|
Fibrinogen, RGD–alginate, hyaluronan blend | Extrusion | Alignment of Schwan cells along the main axis of the bioprinted filament, via shear‐induced alignment of fibrin nanofibers |
[
|
|
gelatin‐fibrin blend, Matrigel Alginate/methyl‐cellulose blend (supporting) | Extrusion | Porous channels printed with the supportive ink and filled with Matrigel to form a pattern of alternated segments containing either NPCs or OPCs. Axonal sprouting and NPC maturation along the channel. No observed OPC maturation or axon myelination |
[
|
| Decellularized brain ECM | Extrusion | Observed insurgence of chemoradiation and temozolomide resistance in cells within bioprinted cultures |
[
|
| Silk fibroin | Extrusion in suspended nanoclay bath | Contextual differentiation of neuronal cells and myoblasts. Formation of synaptic contact with acetylcholine and glutamic acid stimulation of human myocytes |
[
|
Main neural cell types used in bioprinting approaches
| Category | Starting cell type during printing | Terminal neural phenotype obtained | Ref. |
|---|---|---|---|
| Primary cells | Mouse cortical neurons |
Neurons (TUBB3+); Astrocytes (GFAP+) |
[
|
| Rat retinal ganglion cells |
Neurons (TUBB3+); Glial cells (Vimentin+) |
[
| |
| Rat hippocampal and cortical cells | Neurons (TUBB3+) |
[
| |
| Mouse NSCs | Neurons (TUBB3+) |
[
| |
| Rat Schwann cells | Schwann cells (S100b+) | [ | |
| Mouse NSCs |
Neurons (TUBB3+); Astrocytes (GFAP+) |
[
| |
| Rat astrocytes and neurons |
Neurons (MAP2+); Astrocytes (GFAP+) |
[
| |
| Porcine Schwann cells | Schwann cells (S100b+) |
[
| |
| Rat NSCs | Astrocytes (GFAP+) |
[
| |
| Mouse NSCs | Labeled with PKH26 dye |
[
| |
| Rat NPCs |
Neurons (MAP2+); Astrocytes (GFAP+); Oligodendrocytes (Olig2+); Schwann cells (S100b+) |
[
| |
| Rat superior cervical ganglia (SCG) sensory neurons and hippocampal neurons | Neurons (Tau+) |
[
| |
| Rat NSCs |
Neurons (NF‐H+); Astrocytes (GFAP+) |
[
| |
| Established cell lines | Mouse NSC (C17.2) | Morphology under a bright field microscope |
[
|
| Human NPCs (NT2) | Neurons (TUBB3+) |
[
| |
| Mouse NSCs (NE‐4C) | Neurons (TUBB3+) |
[
| |
| Human NSCs (ReNcell CX) |
Neurons (TUBB3+); GABAergic neurons (TUBB3+/GABA+/GAD+); Oligodendrocytes (OLIGO2+); Astrocytes (GFAP+) |
[
| |
| Mouse glioblastoma (GL261) | Glioblastoma (GFAP+/Chil1+) |
[
| |
|
Rat Schwann cells (S16Y); Rat neuronal cell line (PC‐12); Human glioblastoma (D54‐MG) | Not mentioned |
[
| |
| Human glioblastoma (U‐87 MG) | Glioblastoma (F‐actin+) |
[
| |
| Human NPCs (ReNcell VM) |
Neurons (MAP2+); Astrocytes (GFAP+) |
[
| |
| Mouse neuroblastoma (NG108‐15) | Morphology under a bright field microscope |
[
| |
| Rat neuronal cell line (PC‐12) | Neurons (TUBB3+) | [ | |
| Human glioma (U87) | Neurons (TUBB3+) |
[
| |
| Mouse NPCs (NE‐4C) |
Neurons (TUBB3+); Astrocytes (GFAP+) |
[
| |
| Human neuroblastoma (SH‐SY5Y) | SH‐SY5Y (NFH+) |
[
| |
| iPSCs | hiPSCs | Neurons (TUBB3+); |
[
|
| hiPSCs | Ventral midbrain dopaminergic neurons (TUBB3+/TH+/FOXA2+/LMX1A+) |
[
| |
| hiPSC‐derived organ building blocks (OBBs) | Neurons (TUBB3+) |
[
| |
| hiPSC‐derived spinal neuronal progenitor cells (sNPCs) | Neurons (TUBB3+) |
[
| |
| miPSC‐derived oligodendrocyte progenitor cells (OPCs) | Oligodendrocytes (labeled with enhanced green fluorescent protein or mCherry) |
[
| |
| hiPSCs |
Neurons (MAP2+); GABA neurons (GABA+) Astrocytes (GFAP+) |
[
| |
| hiPSC‐derived neuronal and glial precursor cells |
Neurons (MAP2+); Astrocytes (GFAP+) |
[
| |
| hiPSC‐derived NSCs | NSCs (Nestin+/SOX2+/SOX1+/PAX6+) |
[
| |
| hiPSC‐derived neural aggregates | Neurons (TUBB3+) |
[
| |
| hiPSC‐derived NPCs |
Spinal cord motor neurons (TUBB3+/ChaT+); Astrocytes (GFAP+) |
[
|
Figure 3The circuitry of the basal ganglia. The nigrostriatal pathway is the main neuronal pathway degenerated in Parkinson's disease and is composed by midbrain substantia nigra (SN) dopamine neurons that project toward GABA medium spiny neurons in the striatum (STR). The nigrostriatal pathway is itself embedded in a broader circuitry: the basal ganglia. Within basal ganglia, each neuronal cluster can exert excitatory (with glutamate neurons), inhibitory (with GABAergic neurons), or modulatory (with dopamine neurons) action. SNc: substantia nigra pars compacta; SNr: substantia nigra pars reticulata; STN: subthalamic nucleus; GPe: globus pallidus external; and GPi: globus pallidus internal.